France-based GenSight Biologics has unveiled final data from its Phase III Reflect trial (NCT03293524), a randomised, placebo-controlled study to evaluate the safety and efficacy of Lumevoq ...

Eisai and Merck & Co, known as MSD outside the US, said approval for Lenvima (lenvatinib) came through an open-label phase 3 trial, REFLECT, demonstrating a treatment effect on overall survival (OS).

The other trial focused on three men accused of murdering Ahmaud Arbery in Georgia. The defendants claim they were making a citizen's arrest. Critics call it a "lynching." The trials unfold as the ...